Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Australian Stock Exchange  >  CSL Limited    CSL   AU000000CSL8

CSL LIMITED

(CSL)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CSL : New Vaccine Manufacturing Facility

11/15/2020 | 05:49pm EST

For immediate release

16 November 2020

Next-generation influenza vaccine manufacturing facility

to be built in Australia

AUD$800m investment optimises cell-based technology

Global biotechnology leader CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that Seqirus, a wholly owned subsidiary of CSL, plans to invest more than AUD$800 million in the construction of a new biotech manufacturing facility in Melbourne to supply influenza vaccines to Australia and the rest of the world.

This investment decision follows the agreement with the Australian Government for the supply over 10 years of influenza pandemic protection for the Australian population, anti- venoms for Australian snakes, spiders and marine creatures and Q-Fever vaccine.

The new facility, to be built at a site in the Melbourne Airport Business Park, will use innovative cell-based technology to produce influenza vaccine for both seasonal and pandemic purposes. These products will serve the needs of the Australian population and have capacity to support global markets. Construction of the state-of-the-art plant is expected to commence in 2021 with the facility projected to be operational by mid-2026.

The facility will also manufacture Seqirus' proprietary adjuvant MF59® - a substance added to some vaccines to improve immune response and to reduce the amount of antigen needed for each vaccine, enabling more doses to be manufactured more rapidly.

CSL's Chief Executive Officer and Managing Director Paul Perreault said, "Providing safe and effective influenza vaccines is essential in securing our defences against serious public health threats."

"The facility will be an important addition to our global influenza manufacturing supply chain, incorporating the technology platform used in our Holly Springs, North Carolina facility. Cell-influenza vaccine technology offers many advantages over the existing process including being more scalable and offering faster production - particularly important in the case of influenza pandemics.

"As a proudly Australian company, we are pleased to make this investment in world- class advanced manufacturing. This decision will ensure the future of 1,000+ Science Technology Engineering & Manufacturing jobs in Victoria and a supply chain of more than $300 million annually," he said.

Page 2

The Victorian Government will also contribute to the project to reinforce Victoria's already globally significant medical research and biotechnology community.

Authorised by

Fiona Mead

Company Secretary

FURTHER INFORMATION

For further information, please contact:

Investors:

Media:

Mark Dehring

Christina Hickie

Head of Investor Relations

Senior Manager, Communications

CSL Limited

CSL Limited

Telephone: +613 9389 3407

+61 429 609 762

Email: mark.dehring@csl.com.au

Email: christina.hickie@csl.com.au

® Trademarks of CSL Limited or its affiliates.

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

CSL Limited published this content on 15 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 November 2020 22:48:03 UTC


© Publicnow 2020
All news about CSL LIMITED
01/21Australian shares on track to gain 1.5% for week on further U.S. stimulus hop..
RE
01/18Australia shares jump 1% on reports Queensland to lift lockdown curbs
RE
01/12Australia blocks Chinese buyout of builder over security concerns -media
RE
01/11Gold miners drag down Australian shares; NZ falls 2%
RE
01/08Australia shares notch best week in 2 months on broader global rally
RE
01/07MARKET CHATTER : CSL to Finish Production of First Batch of AstraZeneca COVID-19..
MT
01/06Australian shares end 1% lower as U.S. runoff results trickle in
RE
01/05Australia shares open lower as domestic virus concerns weigh
RE
2020Australia shares dip on Sydney restrictions, NZ inches down
RE
2020Australian shares track Wall Street declines; NZ flat
RE
More news
Financials (USD)
Sales 2021 10 127 M - -
Net income 2021 2 254 M - -
Net Debt 2021 4 668 M - -
P/E ratio 2021 42,8x
Yield 2021 1,03%
Capitalization 96 319 M 96 409 M -
EV / Sales 2021 9,97x
EV / Sales 2022 9,25x
Nbr of Employees 27 000
Free-Float 100,0%
Chart CSL LIMITED
Duration : Period :
CSL Limited Technical Analysis Chart | CSL | AU000000CSL8 | MarketScreener
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 228,31 $
Last Close Price 211,70 $
Spread / Highest target 18,6%
Spread / Average Target 7,84%
Spread / Lowest Target -7,82%
EPS Revisions
Managers and Directors
NameTitle
Paul Roger Perreault Chief Executive Officer, Executive Director & MD
Brian Anthony McNamee Chairman
Paul McKenzie Chief Operating Officer
Joy Carolyn Linton Chief Financial Officer
Andrew Cuthbertson Chief Scientific Officer & Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
CSL LIMITED-3.03%96 409
SAMSUNG BIOLOGICS CO.,LTD.-3.87%47 496
BIOGEN INC.10.04%41 462
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.10.88%40 484
ALEXION PHARMACEUTICALS, INC.1.04%34 956
UCB3.67%20 143